India, Feb. 15 -- Intellia Therapeutics, Inc. (NTLA) Thursday announced a strategic collaboration with ReCode Therapeutics to develop gene editing therapies for Cystic fibrosis. The financial aspect of the tie-up is not revealed.
The collaboration is expected to leverage Intellia's proprietary CRISPR-based gene editing platform, including its DNA writing technology, and ReCode's proprietary Selective Organ Targeting lipid nanoparticle delivery platform to correct one or more CF disease-causing gene mutations.
As per the agreement, Intellia will be responsible for the design of the editing strategy, while ReCode will lead the subsequent preclinical, clinical development as well as worldwide commercialization.
Cystic fibrosis is a genetic ...